Measure Title: Shoulder Arthroscopy: Measure of Change in a Validated Shoulder Patient Reported Outcome Following Shoulder Arthroscopy
Measure ID: HF4
High Priority Measure
Measure Type: Patient Reported Outcome
NQS Domain: Effective Clinical Care
Meaningful Measure: Functional Outcomes
Inverse Measure: No
Proportional Measure: No
Continuous Variable: Yes
Ratio Measure: Yes
Performance Rate Calculated: 1, 1st Performance Rate
Risk Adjusted: No
Brief description of the measure:
The change in a validated shoulder measure score will be used as a performance measure for surgeons performing shoulder arthroscopy which includes rotator cuff debridement, biceps tenodesis and acromioplasty procedures. Two measures will be created and reported by each surgeon. Surgeons will report the average shoulder measure change score for patients treated during the observation period. In addition, surgeons will produce a risk-adjusted shoulder measure change score ratio by dividing the average patient shoulder measure change score by the average predicted patient shoulder measure change score calculated using the formula provided. These measures will serve as sports medicine performance measures at the eligible surgeon level.
Eligible validated shoulder patient reported outcome measures include: American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES), Oxford Shoulder Score (OSS), Single Assessment Numeric Evaluation (SANE)
Defining the population: CPT-4 codes will be used to identify patients who received shoulder arthroscopy surgery. Shoulder arthroscopy during the reporting period CPT-4 Codes: 29822, 29823, 29826, 29828, 23430, 29999
Surgeons who performed a minimum of 25 shoulder arthroscopy procedures a year will be eligible to submit this measure.
Time period for data collection and reporting: This measure will be calculated using all patients who underwent shoulder arthroscopy during the observation period. Patients receiving shoulder arthroscopy during the period 18 to 6 months prior to the reporting data will be included in the analysis to ensure 6 months of patient-reported follow-up in the shoulder measure score are available.
Measures: Two surgeon-level performance measures will be reported. The unadjusted measure will be the average 6-month shoulder measure change score across all shoulder arthroscopy patients treated by the surgeon. The adjusted measure will be the ratio of the average shoulder measure change score divided by the average predicted shoulder measure change score for all patients treated by the surgeon.
Unadjusted measure: Average Shoulder Measure Change Score
NUMERATOR: Sum of shoulder measure change scores from pre-surgery to 6-months post-surgery across all shoulder arthroscopy patients in the denominator.
DENOMINATOR: The number of all patients who received shoulder arthroscopy during the observation window from the surgeon.
Risk adjusted measure: Shoulder Measure Change Score Ratio
NUMERATOR: Average 6-month shoulder measure change score for all shoulder arthroscopy patients treated by surgeon.
DENOMINATOR: Average predicted 6-month shoulder measure change score for all shoulder arthroscopy patients treated by surgeon.
Risk adjustment methods and variables:
The predicted 6-month shoulder measure change scores are estimated for each patient using the Center for Effectiveness Research in Orthopaedics’ (CERortho) risk adjustment regression model that includes the following patient variables: age, gender, BMI, smoking status, comorbidities, worker’s compensation status, prior shoulder surgery, tear size, concomitant shoulder procedures, the baseline shoulder measure score, and baseline measures of pain, shoulder function, and quality of life. [2-6] Variables included in the current CERortho risk model are based on information in available databases. CERortho plans to constantly update these specified variables based on input from evaluated surgeons and specialty organizations. Appendix A contains the list of baseline concepts from peer-reviewed literature that are thought to affect outcomes of treatment and will be candidates for future inclusion in the model.